Mucosa-associated lymphoid tissue (MALT) lymphoma is a common type of lymphoma in extranodal sites. The most frequent chromosome translocation associated with MALT lymphoma is t(11;18)(q21;q21), which generates a chimeric protein of c-IAP2 and MALT1/paracaspase. The c-IAP2/MALT1 fusion protein activates the NF-κB pathway, which is considered critical to malignant B cell transformation and lymphoma progression. The mechanism by which this fusion protein activates NF-κB, however, remains unclear. Here we show that self-oligomerization of the c-IAP2/MALT1 protein causes deregulated ubiquitin ligase activity of MALT1/paracaspase. The chimeric protein targets NEMO for polyubiquitination and thereby activates NF-κB. Consistent with this finding, NEMO ubiquitination is increased in t(11;18)(q21;q21)-positive MALT lymphoma samples. Thus, t(11;18)(q21;q21) deregulates MALT1/paracaspase ubiquitin ligase activity, causing constitutive NF-κB activation and promoting tumorigenesis.
Introduction
in CML places the Abelson (ABL) tyrosine kinase gene under the regulation of the promoter for the breakpoint cluster region Tumor development and progression are frequently associated (BCR) gene (de Klein et al., 1982 ). An in-frame chimeric gene with genetic lesions that impact cell proliferation, cell survival, encodes a BCR/Abl fusion protein that is produced only in maangiogenesis, invasion, and metastasis (Hanahan and Wein- lignant cells. Consistent with a causal role for this translocation berg, 2000). Many types of leukemias and lymphomas exhibit in CML, inhibition of the deregulated tyrosine kinase activity of chromosome abnormalities, such as translocations and nonthe BCR/Abl oncoprotein by imatinib (also termed Gleevec) has random gain and loss of chromosomes. Chromosome transloproved effective in treating t(9;22)-positive CML (Druker et al., cations, in particular, have provided important clues to under-2001) . standing the genetic basis of lymphomagenesis. Prominent MALT lymphoma is the most common extranodal non-Hodgexamples include t(14;18)(q32;q21) in human follicular lymkin's lymphoma, arising in sites such as the stomach, lung, and phoma, t(8;14)(q24;q32) in Burkitt's lymphoma, and the t(9; 22) thyroid (Isaacson and Du, 2004) . These lymphomas are comPhiladelphia chromosome in chronic myelogenous leukemia monly derived from a background of chronic inflammation or (CML) (Rowley, 1998) . These translocations are generally assoautoimmune disease. For example, gastric MALT lymphoma is ciated with specific lymphoma subtypes, suggesting that they often preceded by infection with Helicobacter pylori (H. pylori), are causal to disease. Cloning of genes at the translocation while thyroid MALT lymphoma is usually associated with Hasbreakpoints has greatly increased our understanding of these himoto's thyroiditis. These observations suggest that persisoncogenic events. In human follicular lymphoma, the t(14;18) tent inflammation may be linked to cell transformation. translocation juxtaposes the antiapoptotic bcl-2 gene adjacent t(11;18)(q21;q21) is the most frequent chromosomal aberration to the immunoglobulin heavy chain (IGH) gene, resulting in inassociated with MALT lymphoma (Ye et al., 2003) . This translocreased Bcl-2 expression (Rowley, 1998) . In Burkitt's lymcation generates a chimeric transcript fusing the inhibitor of phoma, the t(8;14) translocation juxtaposes the c-myc gene apoptosis-2 (c-IAP2) gene on chromosome 11 to the MALT1 adjacent to the IGH gene, causing upregulated c-Myc expres-(mucosa-associated lymphoid tissue lymphoma translocation gene 1) gene on chromosome 18. Intriguingly, the c-IAP2/ sion (Dalla-Favera et al., 1983) . The Philadelphia chromosome MALT1 fusion protein can potently activate NF-κB in overexpression studies, but wild-type c-IAP2 and MALT1 do not (Akagi et al., 1999; Dierlamm et al., 1999; Uren et al., 2000; Lucas et al., 2001 ). c-IAP2 belongs to a family of IAP proteins characterized by the presence of one to three baculovirus IAP repeat (BIR) domains. c-IAP2 has three BIR domains, one caspase-associated recruitment domain (CARD), and one RING domain ( Figure 1A ). MALT1 contains a death domain (DD), two immunoglobulin-like domains (Ig-like), and a region with homology to caspases ( Figure 1A ). This latter feature led to the naming of MALT1 as human paracaspase. No protease activity has been demonstrated for MALT1/paracaspase; rather, it participates in NF-κB signaling downstream of the antigen receptors by promoting ubiquitination of NEMO (Zhou et al., 2004; Snipas et al., 2004) . The fusion junctions between c-IAP2 and MALT1/paracaspase have been well characterized ( Figure 1A) . The c-IAP2/MALT1 fusion protein always comprises the N-terminal portion of c-IAP2 with three BIR domains and the C-terminal region of MALT1/paracaspase containing an intact caspase-like domain (Akagi et al., 1999; Dierlamm et al., 1999; Baens et al., 2000; Liu et al., 2000; Liu et al., 2002; Ye et al., 2003) . Selection for these domains of c-IAP2 and MALT1/paracaspase to form a functional fusion product strongly suggests their importance and synergy in tumor development.
The NF-κB family of transcription factors plays a key role in inflammatory and innate immune responses (Li and Verma, 2002) . In addition to its importance in immunity, persistent NF-κB activation has been linked to the development of inflammation-associated tumors (Karin et al., 2002; Greten et al., 2004) . Indeed, many human leukemias and lymphomas show constitutive NF-κB activation. The viral oncoprotein v-Rel, a member of the NF-κB family, is sufficient for cell transformation in vitro and in vivo (Gilmore, 1999) . Oncogenic viruses, such as HTLV-1 and Epstein-Barr virus, also activate NF-κB (Karin et al., 2002) . 
The c-IAP2/MALT1 fusion protein induces ubiquitination and NF-κB activation
To investigate the biochemical basis for constitutive NF-κB activation by the c-IAP2/MALT1 fusion protein, we tested whether the case2 form of the c-IAP2/MALT1 fusion protein ( Figure 1A) induced ubiquitination is necessary for case2 to stimulate NF-κB activation. regulates cellular protein ubiquitination. When 293T cells were cotransfected with case2 and hemagglutinin (HA)-tagged
The BIR I domain is essential for case2-induced ubiquitin, case2 increased the overall level of ubiquitin conju-NF-κB activation gates in total cell extracts ( Figure 1B ). In contrast, wild-type
To investigate the contribution of the BIR domains from c-IAP2 MALT1/paracaspase or the C453A mutant of MALT1/paracasin case2-induced NF-κB activation, N-terminal deletion mupase did not induce ubiquitination ( Figure 1B) . A case2 mutant tants of case2 were generated ( Figure 2A ). These mutants were that had the conserved cysteine residue in the caspase-like transfected into 293T cells and tested for their ability to actidomain replaced with alanine induced total cellular ubiquitinavate a NF-κB-dependent reporter gene. Case2 mutants lacking tion similar to wild-type case2 ( Figure 1B ), so we conclude that BIR I failed to activate NF-κB, whereas the case2 mutant that the increased ubiquitination was not dependent on the hyporetained BIR I but lacked BIR II and BIR III stimulated considerthetical cysteine protease activity of MALT1/paracaspase. able NF-κB activity ( Figure 2B ). These results indicate that the Case2 and the case2 mutant also stimulated equivalent NF-κB BIR I domain from c-IAP2 is both necessary and sufficient for activation (data not shown). These results are consistent with NF-κB activation by the case2 fusion protein. recent findings that the MALT1/paracaspase C453A mutant enPrevious studies have shown that Bcl10 promotes oligomerhances rather than decreases Bcl10-stimulated NF-κB activaization of MALT1/paracaspase to activate NF-κB (Zhou et al., tion (Lucas et al., 2001; Zhou et al., 2004; Sun et al., 2004) .
2004; Sun et al., 2004) . Because artificial crosslinking of the Thus, NF-κB activation by case2 or Bcl10 is not linked to any caspase-like domain of MALT1/paracaspase has been shown predicted cysteine protease activity of MALT1/paracaspase.
to activate NF-κB (Lucas et al., 2001; Zhou et al., 2004 ; Sun et Because case2 overexpression stimulates ubiquitination and al., 2004), we tested whether the BIR domains from c-IAP2, activates NF-κB, whereas MALT1/paracaspase expression particularly BIR I, might oligomerize case2 and thereby activate does neither, it is likely that these two events are mechanisti-NF-κB. Flag-tagged case2 and either HA-tagged case2 or HAcally linked. We confirmed that the bands observed in Figure  tagged case2 deletion mutants were cotransfected into 293T 1B were ubiquitin conjugates by incubating the cell lysates with cells. HA-case2 and the HA-case2 mutant retaining BIR I coimthe deubiquitinating enzyme Usp2. Purified Usp2 abrogated munoprecipitated with Flag-case2, whereas the HA-tagged the bands, as revealed by anti-HA immunoblotting, indicating case2 mutants lacking BIR I did not associate with Flag-case2 that ubiquitin was cleaved from ubiquitinated proteins. Usp2
( Figure 2C ). These results show that the BIR I domain can serve failed to cleave the ubiquitin conjugates in the presence of as an oligomerization motif and thus might regulate case2 NEM, an alkylating agent that inhibits deubiquitinating enfunction. Interestingly, the BIR domains of Op-IAP, another IAP zymes ( Figure 1C) . family member, have also been shown to mediate Op-IAP Ubiquitination is a reversible posttranslational modification in oligomerization and regulate Op-IAP function (Hozak et al., which the C terminus of 76 amino acid ubiquitin is conjugated 2000). The BIR I-only case2 mutant, but not those mutants with to a lysine residue in the target protein. The target protein can BIR I deleted, induced total cellular ubiquitination approaching be modified by addition of either a single ubiquitin moiety or a that of full-length case2 ( Figure 2D ), indicating that BIR I-medipolyubiquitin chain that has ubiquitins linked via specific lysine ated oligomerization is essential for both ubiquitination and residues. The type of ubiquitin linkage often determines the NF-κB activation by case2. fate of polyubiquitinated proteins. K48-linked polyubiquitination generally targets a protein for degradation in the proteaAn Ig-like domain C-terminal to the caspase-like domain some, whereas K63-linked polyubiquitination often regulates is required for NF-κB activation by case2 protein function or protein-protein interactions (Pickart, 2001) .
To investigate which domains from MALT1/paracaspase conFor example, recent studies have indicated that assembly of tribute to NF-κB activation by case2, C-terminal deletion musignaling complexes required for activation of NF-κB involves tants of case2 were generated ( Figure 3A) . Surprisingly, case2 K63-linked ubiquitination of proteins such as TRAF2, TRAF6, del1 mutant, which has an intact caspase-like domain but and NEMO (Burns and Martinon, 2004) . To determine the prelacks further C-terminal amino acids, could not activate exdominant ubiquitin linkage induced by case2, 293T cells were pression of a NF-κB-dependent reporter gene ( Figure 3B ). cotransfected with case2 and either wild-type ubiquitin, ubiquiCloser examination of the C terminus of MALT1/paracaspase tin that had all but one lysine (K48 or K63) mutated to arginine, revealed an Ig-like domain following the caspase-like domain. or ubiquitin that had all of its seven lysines changed to arginine.
An additional 100 amino acids come after the Ig-like domain, Immunoblotting for the HA tag on the various ubiquitins rebut these do not resemble any known structural motif (Figure vealed that case2 increased cellular ubiquitination only when 3A). Retention of the Ig-like domain was found to be necessary K63 was available for conjugation ( Figure 1D ). K63-linked for NF-κB activation, while the last 100 amino acids were disubiquitination can be catalyzed, in part, by the ubiquitin-conjupensable ( Figure 3B ). These results indicate that the C-terminal gating E2 enzyme Ubc13 in a heterodimeric complex with Ig-like domain from MALT1/paracaspase is required for NF-κB either Uev1a or Mms2 (Hofmann and Pickart, 1999; VanDe- activation by case2. mark et al., 2001). We tested whether Ubc13 is required for Recently, two consensus TRAF6 binding motifs were recase2-induced ubiquitination and NF-κB activation by pretreatported to be present in the C terminus of MALT1/paracaspase ing 293T cells with or without siRNAs targeting Ubc13. Knock- (Sun et al., 2004) , and it was suggested that the Bcl10/MALT1/ down of Ubc13 protein abrogated both case2-induced total paracaspase complex engages TRAF6 to activate NF-κB. Both cellular ubiquitination ( Figure 1E ) and NF-κB activation ( Figure  TRAF6 binding sites were deleted in the case2 del1 mutant, so we further investigated the contribution of these two sites to 1F). These data are consistent with the hypothesis that case2- . BIR I domain is essential for case2-induced NF-κB activation case2 or case2 deletions as indicated. NF-κB fold activation was determined by NF-κB reporter assay relative to the vector control. Data repre-A: Schematic representation of case2 and case2 deletional mutants. Fullsent mean ± SEM of three independent experiments. length (FL) case2 was compared to deletion mutants lacking either the BIR C: 293T cells were transfected with NF-κB reporter plasmids together with I domain alone (⌬BIR I case2), both BIR I and BIR II (BIR III only case2), or BIR case2, case2 (E653A), case2 (E806A), or case2 (E653A/E806A; AA) as indi-II and BIR III domains (BIR I only case2).
cated. Data are expressed relative to case2 control and represent the B: 293T cells were transfected with NF-κB reporter plasmids together with mean ± SEM of three independent experiments. case2 or case2 mutants as indicated. NF-κB activation fold was deter-D: Ubc13 and HA-case2 or HA-tagged case2 deletion mutants were transmined by NF-κB reporter assay relative to the vector control. Data reprefected into 293T cells. Association between Ubc13 and HA-tagged case2 sent mean ± SEM of three independent experiments. ⌬BIR I case2 failed to deletion mutants was determined by immunoprecipitation with HA monostimulate NF-κB activation, whereas BIR I only case2 still activated NF-κB.
clonal antibody followed by immunoblotting with anti-Ubc13 antibody. C: Flag-case2 and either HA-case2 or HA-tagged case2 deletion mutants were transfected into 293T cells. Interactions between Flag-case2 and HAtagged case2 deletion mutants were determined by immunoprecipitation with Flag monoclonal antibody followed by immunoblotting with antibody to HA. tion ( Figure 1E ), and because we have shown previously that D: HA-case2 or HA-case2 deletional mutants were transfected with Flagthe C-terminal half of MALT1/paracaspase catalyzes ubiquitiubiquitin into 293T cells. Ubiquitination was determined by immunoblotting for Flag.
nation together with Ubc13/Mms2 (Zhou et al., 2004) , we tested whether the C-terminal deletions of case2 impacted E2 binding. HA-case2 or HA-tagged case2 deletion mutants were cotransfected with Ubc13 into 293T cells. Ubc13 coimmunocase2-induced NF-κB activation by generating full-length precipitated with full-length case2 and the case2 del2 mutant, case2 point mutants E653A, E806A, and E653A/E806A ( Figure  which retains the Ig-like domain. No interaction was observed 3C). All three case2 mutants activated NF-κB ( Figure 3C ), indibetween Ubc13 and the case2 del1 mutant lacking the Ig-like cating that these potential TRAF6 binding sites may not be redomain ( Figure 3D ). The importance of this Ig-like domain in quired for case2 to activate NF-κB.
Because Ubc13 is required for case2-induced NF-κB activacase2 for the recruitment of Ubc13 offers an explanation for why deletion of this domain renders case2 unable to either activate NF-κB ( Figure 3B ) or increase total cellular ubiquitination (data not shown).
Case2 induces NEMO ubiquitination
To determine whether case2 activates NF-κB in a fashion similar to Bcl10 (Zhou et al., 2004; Sun et al., 2004) , we tested whether case2 increased ubiquitination of cotransfected NEMO in 293T cells. Detection of ubiquitin conjugates was facilitated by transfection of HA-tagged ubiquitin. Case2 did induce NEMO ubiquitination, as determined by immunoblotting with NEMO and HA ( Figure 4A ). NEMO has a highly conserved lysine residue (K399) within its zinc finger, which, when mutated to arginine, markedly decreased NEMO ubiquitination in response to case2 ( Figure 4A ). The significance of polyubiquitination on K399 within NEMO to case2-induced NF-κB activation was assessed by transfecting case2 into NEMO-deficient 5R cells. Consistent with a previous study, case2 did not activate NF-κB in NEMO-deficient 5R cells (Lucas et al., 2001; Figure 4B) . Significantly, 5R cells reconstituted with wild-type NEMO activated NF-κB in response to case2, but activation of NF-κB was much weaker when cells were reconstituted with the NEMO K399R mutant ( Figure 4B ). These results indicate that ubiquitination of NEMO on K399R is important for full NF-κB activation by case2. The contribution of ubiquitination to case2-induced NF-κB activation was confirmed using the deubiquitinating enzyme CYLD; case2-induced NF-κB activation in 293T cells was suppressed effectively by CYLD ( Figure 4C ), and this suppression correlated with a severe reduction in NEMO ubiquitination ( Figure 4D ).
NEMO ubiquitination is increased in t(11;18) MALT lymphoma tumor samples
Next, we examined the ubiquitination status of NEMO in t(11;18)-positive MALT lymphoma samples that transcribed MALT lymphoma samples (G5661 and G6071), but, as ex-B: NEMO-deficient 5R cells were cotransfected with case2 and NEMO (wt) pected, were not detected in human tonsil samples ( Figure 4E ).
or NEMO mutant K399R (mt). Case2-stimulated NF-κB activation was deter-NEMO ubiquitination in these samples was examined by immined by NF-κB reporter assay. Data represent the mean ± SEM of three munoprecipitation with NEMO antibody followed by immuindependent experiments. C: A NF-κB reporter plasmid and case2 were transfected into 293T cells with noblotting with anti-ubiquitin antibody ( Figure 4E ). More polyor without CYLD. NF-κB activation was determined by NF-κB reporter assay. were used as negative controls (Ton1, Ton2). Ubiquitination of NEMO, which was first immunoprecipitated from denatured lysates (Zhou et al., 2004) ,
Discussion
was determined by immunoblotting with anti-ubiquitin antibody as indicated.
A causal relationship between inflammation and cancer has been suspected for many years, but the link between the two remains poorly understood. Chronic infection and inflammation tion, and that expression of the c-IAP2/MALT1 fusion protein might affect cells directly or indirectly to promote their maligthen drives progression to MALT lymphoma. Unfortunately, nant transformation. In gastric MALT lymphoma, the t(11; 18) attempts to generate transgenic mice expressing the c-IAP2/ translocation is closely linked to infection with CagA-positive MALT1 fusion protein in the B cell lineage have been unsucstrains of H. pylori (Ye et al., 2003) , which elicit significant incessful (V.M.D., unpublished data), so it remains to be seen flammatory responses. It is tempting to speculate that the whether expression of the c-IAP2/MALT1 fusion protein alone t(11;18) translocation occurs in premalignant lesions as a consequence of persistent B cell activation during chronic infecpromotes tumor development.
Two other rare, but recurrent, chromosomal translocations antibiotics, suggesting that c-IAP2/MALT1 activates NF-κB sufficiently to stimulate antigen-independent growth. found in MALT lymphoma are t(1;14)(p22;q32) (Isaacson and In summary, our study provides an example of a chromoDu, 2004) and t(14;18)(q32;q21) (Sanchez-Izquierdo et al., somal translocation that contributes to a human malignancy Streubel et al., 2003) . t(1;14)(p22;q32) juxtaposes the by impacting the activity of an ubiquitin ligase. Given that the bcl10 gene to the immunoglobin (Ig) locus, resulting in upreguubiquitin/proteasome (UPS) system is involved in multiple aslated Bcl10 expression. t(14;18)(q32;q21) places the MALT1 pects of cell proliferation, differentiation, and survival, it is likely gene under the control of the enhancer region of the IGH gene that UPS deregulation will emerge as a critical factor in tumoriand elevates MALT1/paracaspase expression. Both Bcl10 and genesis. Drugs such as the general proteasome inhibitor Vel-MALT1/paracaspase are required for antigen receptor-stimcade, which has been approved for multiple myeloma therapy, ulated NF-κB activation and lymphocyte proliferation (Ruland will hopefully exploit this possibility. For t(11;18)-positive MALT et al., 2001 MALT et al., , 2003 Ruefli-Brasse et al., 2003; Zhou et al., 2004) .
lymphoma, specific inhibition of c-IAP2/MALT1 ubiquitin ligase In fact, Bcl10 and MALT1 form a complex and synergize in the activity might be beneficial. activation of NF-κB-dependent gene transcription (Lucas et al., 2001) . Given that the c-IAP2/MALT1 fusion protein also acti-
Experimental procedures
vates the NF-κB pathway, it seems likely that all three distinct chromosomal translocations contribute to MALT lymphoma pathogenesis by allowing antigen-independent NF-κB activaCells, cell culture, antibodies, plasmids, tion to promote growth and expansion of the lymphoma clone.
and MALT lymphoma samples
Recently, it was suggested that MALT1/paracaspase recruits Human kidney epithelial (HEK) 293T cells were grown in DMEM supple-TRAF6 to activate NF-κB signaling (Sun et al., 2004) . T cells mented with 10% FBS at 37°C in the presence of 10% CO 2 . All constructs from TRAF6-deficient mice, however, are reported to proliferate for mammalian protein expression were generated in the pRK5B vector with a Flag-or HA-epitope tag placed at the NH2-terminal of the protein as normally in response to crosslinking antibodies to CD3 and indicated. The breakpoint in the cIAP2 gene from both G5661 and G6071 CD28 (Lomaga et al., 1999) . By contrast, Bcl10-or MALT1/ is nucleotide 2048. The breakpoint in the MALT1 gene in G5661 and G6071 paracaspase-deficient T cells neither activate NF-κB nor prolifis nucleotide 1123 and 814, respectively. erate upon TCR engagement (Ruland et al., 2001 (Ruland et al., , 2003 RuefliBrasse et al., 2003) . These observations argue against an were synthesized by Dharmacon as described previously (Zhou et al., Mutation of the proposed TRAF6 binding sites in case2 did 2004) . 36 hr after adding siRNAs, cells were transfected with the indicated not attenuate case2-induced NF-κB activation ( Figure 3C ), nor expression plasmids and cultured for an additional 36 hr before harvesting.
could we detect the association of TRAF6 with case2 (Supplemental Figure S1 ). In addition, siRNA-mediated knockdown of NF-κB reporter assay 293T and 5R cells were transfected with the indicated plasmids using Lipo-TRAF6 did not inhibit case2-stimulated NF-κB activation (Supfectamine 2000 (Invitrogen). 36 hr posttransfection, NF-κB luciferase activplemental Figure S2 ). These results suggest that the fusion proity was measured using the Promega Dual Luciferase Reporter Assay systein engages NF-κB in a TRAF6-independent manner, although tem (normalized to control luciferase activity) as previously described (Zhou it cannot be ruled out that another member of the TRAF family et al., 2004) . might substitute for TRAF6.
Overexpressed case2, like Bcl10 (Zhou et al., 2004) , induces antigen receptor stimulation triggers assembly of the Bcl10-
